Xilio Therapeutics (XLO) Common Equity (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Common Equity data on file, last reported at $72.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 577.99% year-over-year to $72.5 million; the trailing twelve-month figure through Mar 2026 stood at $72.5 million (up 577.99% YoY), and the FY2025 full-year result was $35.3 million, up 100.44% from the prior year.
• Common Equity grew to $72.5 million in Q1 2026, from $35.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $166.1 million in Q1 2022 to a low of -$8.1 million in Q3 2025.
• A 5-year average of $58.8 million and a median of $36.8 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 138.6% in 2025 and surged 577.99% in 2026, its largest moves.
• Tracing XLO's Common Equity over 5 years: stood at $105.6 million in 2022, then plunged by 65.14% to $36.8 million in 2023, then sank by 52.21% to $17.6 million in 2024, then surged by 100.44% to $35.3 million in 2025, then jumped by 105.67% to $72.5 million in 2026.
• Business Quant data shows XLO's Common Equity at $72.5 million in Q1 2026, $35.3 million in Q4 2025, and -$8.1 million in Q3 2025.